Atai life sciences announces strategic investment in beckley psytech to accelerate the clinical development of short-duration psychedelics

New york and berlin, jan. 04, 2024 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai” or “company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in beckley psytech limited (“beckley psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
ATAI Ratings Summary
ATAI Quant Ranking